The investigator writes that the majority of malignant tumors are resistant to radio- or chemotherapy in advanced stages mainly due to loss of p53 function. New tumor gene therapy approaches must consider targeting every cell in the primary tumor and all metastases with a maximal cytotoxic index for cancer cells. First generation adenovirus (Ad) vectors are attractive for cancer therapy because of their potential to transduce all tumor sites after systemic application. These vectors are deleted in the E1 region, rendering them highly replication-defective. This proposal is based on the observation that E1-deleted Ad vectors replicate selectively in HPV associated cervical carcinoma cells because the HPV E6/E7 proteins which are responsible for the maintenance of the malignant phenotype effectively complement the deleted Ad E1 proteins. The goal is to develop oncolytic Ad vectors for cervical cancer that replicate in tumor-specifically and disseminate throughout the tumor, selectively killing all tumor cells by viral cytolysis or p53-independent apoptosis. The studies will be performed in immunodeficient mice with hepatic tumors derived from cervical carcinoma cell lines or in immunocompetent mice with HPV induced tumors.
The specific aims are: 1. To develop an expression system based on a unique Ad-AAV hybrid vector, which activates a tumor-specific promoter only upon viral DNA replication. 2. To test whether virus dissemination throughout the tumor can be obtained if virus release from infected tumor cells is supported by cytolysis or apoptosis induced after viral replication is completed. For this purpose the investigators will use the AD-AAV system and investigate virus spread and anti-tumor efficacy after a) E3-11.6K expression, and b) expression of a transdominant i-kB mutant to sensitize tumor cells to apoptosis induced by TNF treatment or TRAIL expression. 3. To investigate the effect of antiviral immune responses on oncolytic vector spread and, if required, to suppress these responses by expression of Ad E3 proteins and/or transient immuno-modulation. These studies will give valuable information about the influence of apoptosis and host immune responses on replication-competent Ad vectors developed for tumor gene therapy. This proposal may provide a means for treatments of cervical carcinoma and has potential application for other malignancies with deregulated pRb/p16 functions that allow for replication of E1-deleted Ad vectors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA080192-04
Application #
6489188
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Yovandich, Jason L
Project Start
1999-03-18
Project End
2003-12-31
Budget Start
2002-01-01
Budget End
2002-12-31
Support Year
4
Fiscal Year
2002
Total Cost
$225,693
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Yumul, Roma; Richter, Maximilian; Lu, Zhuo-Zhuang et al. (2016) Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models. Hum Gene Ther 27:325-37
Saydaminova, Kamola; Strauss, Robert; Xie, Min et al. (2016) Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells. Cancer Biol Ther 17:1079-1088
Wang, Hongjie; Ducournau, Corinne; Saydaminova, Kamola et al. (2015) Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1. J Virol 89:10841-59
Richter, Maximilian; Yumul, Roma; Wang, Hongjie et al. (2015) Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin. Mol Ther Methods Clin Dev 2:15005
Zhang, Bo; Yan, Yuhua; Jin, Jie et al. (2015) Two types of functionally distinct fiber containing structural protein complexes are produced during infection of adenovirus serotype 5. PLoS One 10:e0117976
Carter, Darrick; Lieber, André (2014) Protein engineering to target complement evasion in cancer. FEBS Lett 588:334-40
Lu, Zhuo-Zhuang; Wang, Hongjie; Zhang, Yiyi et al. (2013) Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells. PLoS Pathog 9:e1003718
Beyer, Ines; Cao, Hua; Persson, Jonas et al. (2013) Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques. Mol Ther 21:291-9
Wang, Hongjie; Yumul, Roma; Cao, Hua et al. (2013) Structural and functional studies on the interaction of adenovirus fiber knobs and desmoglein 2. J Virol 87:11346-62
Strauss, Robert; Bartek, Jiri; Lieber, André (2013) Analysis of EMT by flow cytometry and immunohistochemistry. Methods Mol Biol 1049:355-68

Showing the most recent 10 out of 52 publications